TY - JOUR
T1 - Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival
AU - Khan, D
AU - Vasu, Srividya
AU - Moffett, Charlotte
AU - Irwin, Nigel
AU - Flatt, Peter
PY - 2016/11/15
Y1 - 2016/11/15
N2 - Recent evidence suggests that the classic gut peptide, Peptide YY (PYY), could play a fundamental role in endocrine pancreatic function. In the present study expression of PYY and its NPY receptors on mouse islets and immortalised rodent and human beta-cells was examined together with the effects of both major circulating forms of PYY, namely PYY(1-36) and PYY(3-36), on beta-cell function, murine islet adaptions to insulin deficiency/resistance, as well as direct effects on cultured beta-cell proliferation and apoptosis. In vivo administration of PYY(3-36), but not PYY(1-36), markedly (p <0.05) decreased food intake in overnight fasted mice. Neither form of PYY affected glucose disposal or insulin secretion following an i.p. glucose challenge. However, in vitro, PYY(1-36) and PYY(3-36) inhibited (p <0.05 to p <0.001) glucose, alanine and GLP-1 stimulated insulin secretion from immortalised rodent and human beta-cells, as well as isolated mouse islets, by impeding alterations in membrane potential, [Ca2+]i and elevations of cAMP. Mice treated with multiple low dose streptozotocin presented with severe (p <0.01) loss of beta-cell mass accompanied by notable increases (p <0.001) in alpha and PP cell numbers. In contrast, hydrocortisone-induced insulin resistance increased islet number (p <0.01) and beta-cell mass (p <0.001). PYY expression was consistently observed in alpha-, PP- and delta-, but not beta-cells. Streptozotocin decreased islet PYY co-localisation with PP (p <0.05) and somatostatin (p <0.001), whilst hydrocortisone increased PYY co-localisation with glucagon (p <0.05) in mice. More detailed in vitro investigations revealed that both forms of PYY augmented (p <0.05 to p <0.01) immortalised human and rodent beta-cell proliferation and protected against streptozotocin-induced cytotoxicity, to a similar or superior extent as the well characterised beta-cell proliferative and anti-apoptotic agent GLP-1. Taken together, these data highlight the significance and potential offered by modulation of pancreatic islet NPY receptor signalling pathways for preservation of beta-cell mass in diabetes.
AB - Recent evidence suggests that the classic gut peptide, Peptide YY (PYY), could play a fundamental role in endocrine pancreatic function. In the present study expression of PYY and its NPY receptors on mouse islets and immortalised rodent and human beta-cells was examined together with the effects of both major circulating forms of PYY, namely PYY(1-36) and PYY(3-36), on beta-cell function, murine islet adaptions to insulin deficiency/resistance, as well as direct effects on cultured beta-cell proliferation and apoptosis. In vivo administration of PYY(3-36), but not PYY(1-36), markedly (p <0.05) decreased food intake in overnight fasted mice. Neither form of PYY affected glucose disposal or insulin secretion following an i.p. glucose challenge. However, in vitro, PYY(1-36) and PYY(3-36) inhibited (p <0.05 to p <0.001) glucose, alanine and GLP-1 stimulated insulin secretion from immortalised rodent and human beta-cells, as well as isolated mouse islets, by impeding alterations in membrane potential, [Ca2+]i and elevations of cAMP. Mice treated with multiple low dose streptozotocin presented with severe (p <0.01) loss of beta-cell mass accompanied by notable increases (p <0.001) in alpha and PP cell numbers. In contrast, hydrocortisone-induced insulin resistance increased islet number (p <0.01) and beta-cell mass (p <0.001). PYY expression was consistently observed in alpha-, PP- and delta-, but not beta-cells. Streptozotocin decreased islet PYY co-localisation with PP (p <0.05) and somatostatin (p <0.001), whilst hydrocortisone increased PYY co-localisation with glucagon (p <0.05) in mice. More detailed in vitro investigations revealed that both forms of PYY augmented (p <0.05 to p <0.01) immortalised human and rodent beta-cell proliferation and protected against streptozotocin-induced cytotoxicity, to a similar or superior extent as the well characterised beta-cell proliferative and anti-apoptotic agent GLP-1. Taken together, these data highlight the significance and potential offered by modulation of pancreatic islet NPY receptor signalling pathways for preservation of beta-cell mass in diabetes.
KW - Apoptosis
KW - Beta-cell
KW - Diabetes
KW - NPYR
KW - Peptide YY (PYY)
KW - Proliferation
UR - https://pure.ulster.ac.uk/en/publications/islet-distribution-of-peptide-yy-and-its-regulatory-role-in-prima-3
U2 - 10.1016/j.mce.2016.07.020
DO - 10.1016/j.mce.2016.07.020
M3 - Article
VL - 436
SP - 102
EP - 113
JO - Molecular and Cellular Endocrinology
JF - Molecular and Cellular Endocrinology
ER -